Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.
|Grade||Last Price||% Change||Price Change|
RARE closed down 1.23 percent on Thursday, May 24, 2018, on 88 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical RARE trend table...|
|Date||Alert Name||Type||% Chg|
|May 24||Wide Bands||Range Expansion||0.00%|
|May 24||Overbought Stochastic||Strength||0.00%|
|May 23||180 Bullish Setup||Bullish Swing Setup||-1.23%|
|May 23||Wide Bands||Range Expansion||-1.23%|
|May 23||Overbought Stochastic||Strength||-1.23%|
|May 22||Slingshot Bullish||Bullish Swing Setup||0.50%|
|May 22||NR7||Range Contraction||0.50%|
|May 22||Wide Bands||Range Expansion||0.50%|
|May 22||Overbought Stochastic||Strength||0.50%|
|May 21||Wide Bands||Range Expansion||-0.45%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RARE news...
|52 Week High||71.99|
|52 Week Low||41.67|
|200-Day Moving Average||51.8704|
|50-Day Moving Average||55.0644|
|20-Day Moving Average||59.731|
|10-Day Moving Average||64.399|
|Average True Range||2.4909|
|Chandelier Exit (Long, 3 ATRs )||59.2573|
|Chandelier Exit (Short, 3 ATRs )||57.3327|
|Upper Bollinger Band||70.15|
|Lower Bollinger Band||49.312|
|Percent B (%b)||0.73|
|MACD Signal Line||2.9234|
|Market Cap||2.75 Billion|
|Num Shares||42.6 Million|
|Price-to-Earnings (P/E) Ratio||-9.57|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||68.13|
|Resistance 3 (R3)||68.47||67.60||67.53|
|Resistance 2 (R2)||67.60||66.68||67.43||67.32|
|Resistance 1 (R1)||66.05||66.10||65.62||65.71||67.12|
|Support 1 (S1)||63.63||64.26||63.20||63.29||61.88|
|Support 2 (S2)||62.76||63.68||62.59||61.68|
|Support 3 (S3)||61.21||62.76||61.48|
|Support 4 (S4)||60.87|